New Developments in Polio Vaccine
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Infectious Diseases".
Deadline for manuscript submissions: 20 June 2024 | Viewed by 123
Special Issue Editor
Interests: human poliovirus 1; oral poliomyelitis vaccine; poliomyelitis; enterovirus; heterologous immunity; immunity
Special Issue Information
Dear Colleagues,
The discovery of two vaccines against poliomyelitis—first the inactivated poliovirus vaccine (IPV) created by Jonas Salk, and soon after the live oral poliovirus vaccine (OPV) by Albert Sabin—was an enormous medical breakthrough of the mid-20th century. Their creation and use established a paradigm for other vaccines. Their evolution over the more than 60 years since their introduction is a perfect illustration of the need to continuously update medical products to match the changing epidemiological, economical, and societal landscape. OPV was so successful that in 1988, the World Health Assembly resolved to completely eradicate poliomyelitis by the year 2000. Even though the deadline was not met and polio eradication remains a moving target 35 years later, the Global Polio Eradication Initiative achieved tremendous progress. It also became clear that the current versions of IPV and OPV are not optimal for a post-eradication world. IPV is made from highly virulent virus strains and does not prevent virus transmission. OPV causes rare but serious adverse events and can trigger new outbreaks caused by a vaccine-derived virus. Therefore, finishing the eradication campaign and making its success irreversible requires the development and introduction of a new generation of polio vaccines. This Special Issue is devoted to these ongoing efforts.
Dr. Konstantin Chumakov
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- polio vaccines
- poliomyelitis
- inactivated poliovirus vaccine (IPV)
- live oral poliovirus vaccine (OPV)
